Skip to search formSkip to main contentSkip to account menu

Cytochrome P-450 CYP2D6

Known as: Debrisoquine Hydroxylase, Cytochrome P 450 CYP2D6, P450 2D6, Cytochrome 
A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR… 
National Institutes of Health

Related topics

Related topics

27 relations
AromataseCYP19A1 protein, humanCYP2C18 protein, humanCYP2C19 gene

Broader (4)

Aryl Hydrocarbon HydroxylasesCytochrome P450Mixed Function OxygenasesXenobiotic Monooxygenases

Narrower (1)

Cytochrome P450 2D6, human

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
the Context of CYP 2 D 6 Pharmacogenomics : Current State of the Art
2011
2011
Tamoxifen and CYP 2D6 inhibitors: caution.
  • Prescrire international
  • 2011
  • Corpus ID: 44640938
Tamoxifen, an oestrogen antagonist, is the standard hormone treatment for breast cancer. It is extensively transformed into its… 
2010
2010
Selections from a literature search on the effects , mechanism of action , and metabolism of mCPP , the principal metabolite of Trazodone , with references
Trazodone, a triazolepyridine derivate, is both chemically and pharmacologically distinct from other serotonin reuptake… 
2005
2005
Histamine and 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline are competitive inhibitors of debrisoquine 4-monooxygenase in rat liver
The effects of histamine and 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline(salsolinol) on debrisoquine 4-monooxygenation… 
2005
2005
Fast and slow metabolizers of Hoasca.
Abstract Harmine, a major alkaloid in ayahuasca (hoasca), is a selective and reversible inhibitor of the enzyme monoamine oxidase… 
1998
1998
Interets cliniques des polymorphismes genetiques : exemples du cytochrome p450 2d6 (cyp2d6) et de la n-acetyltransferase (nat2) (doctorat : toxicologie)
1997
1997
Polymorphisme genetique du cytochrome p450 2d6 (cyp2d6) dans la population europeenne
1992
1992
Polymorphisme genetique du locus cytochrome p450iid (debrisoquine hydroxylase) : implication en pharmacogenetique
La deficience de transformation metabolique de type debrisoquine/sparteine est un defaut monogenique a transmission autosomale… 
1984
1984
A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.
The present study compares the debrisoquine monooxygenase and the sparteine monooxygenase activities of human liver microsomes… 
1982
1982
[Clinically significant inherited differences in the mode of action of drugs].
An important source of interindividual differences in drug action are inherited differences in the pharmacokinetics and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)